Pila Pharma AB is a clinical-stage biotechnology company that develops oral TRPV1 antagonists as potential treatments for obesity and diabetes. The company serves patients suffering from these metabolic conditions by advancing innovative, non-injectable drug candidates through preclinical and clinical research.
Subscribe to see Pila Pharma AB’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Pila Pharma AB is a pharmaceuticals company headquartered in Sweden. Xcout tracks 3 named people at Pila Pharma AB, including Dorte X. Gram (Chairman of the Board and CSO).
A few of Pila Pharma AB's closest competitors — see the full list of competitors and alternatives →
Saniona AB is a clinical-stage biopharmaceutical company that discovers and develops treatments for neurological disorders and rare diseases. The company utilizes its proprietary ion channel drug discovery engine and proprietary molecule library to advance a pipeline of potential new medicines targeting conditions such as epilepsy and hypothalamic obesity.
Orexo AB is a pharmaceutical company that specializes in developing innovative drug delivery technologies, notably its powder-based AmorphOX platform. The company advances proprietary and partnered pharmaceutical products, including treatments, vaccines, and nasal delivery formulations, serving patients and healthcare partners globally.
Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees. In 2018, they opened a subsidiary in the US. Zealand Pharma forms part of the Danish-Swedish life science cluster Medicon Valley.
Ilya Pharma AB is a Swedish biotechnology company developing biologic medicines based on engineered lactic-acid bacteria that deliver therapeutic proteins locally at mucosal surfaces. Its development programs have focused on local treatments for inflammatory, wound-healing, and other tissue-repair conditions.
Villya LLC is a pharmaceutical company that develops second-generation medications and proprietary delivery technologies aimed at improving the function, solubility, and administration of traditional drugs and peptides. Using patented technology, the company focuses on creating water-soluble formulations and alternative delivery methods, including oral options for treatments such as Praziquantel, Sildenafil, Semaglutide, and insulin.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.